Mitapivat

(Pyrukynd®)

Mitapivat

Drug updated on 11/15/2023

Dosage FormTablet (oral; 5 mg, 20 mg, 50 mg)
Drug ClassPyruvate kinase activators
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

Product Monograph / Prescribing Information

Document TitleYearSource
Pyrukynd (mitapivat) Prescribing Information. 2022Agios Pharmaceuticals, Inc., Cambridge, MA

Systematic Reviews / Meta-Analyses